Objective Controlled ovarian stimulation (COS) using recombinant follicle-stimulating hormone (rFSH) is the main treatment in assisted reproduction. We performed a pharmacogenetic analysis of bone morphogenetic protein 15 (BMP15) gene using single nucleotide polymorphisms (SNPs) in COS. We also investigated the role of the BMP15 gene in ovarian hyperstimulation syndrome (OHSS).
Objective Controlled ovarian stimulation (COS) using recombinant follicle-stimulating hormone (rFSH) is the main treatment in assisted reproduction. We performed a pharmacogenetic analysis of bone morphogenetic protein 15 (BMP15) gene using single nucleotide polymorphisms (SNPs) in COS. We also investigated the role of the BMP15 gene in ovarian hyperstimulation syndrome (OHSS).
Methods We analysed different intragenic SNPs located within the BMP15 gene in 307 women treated with rFSH, evaluating its involvement in COS outcome.
Results First, we analysed two polymorphisms, by applying different tests for genetic association, and we found a minimum P-value in patients producing Z 12 follicles in COS (high responders) in both polymorphisms of the BMP15 gene. Using bi-directional DNA sequencing, we identified two additional single nucleotide DNA variants. Second, we conducted association studies with all polymorphisms together, and noticed that none of them seemed to fully explain the association of the BMP15 gene with over-response to rFSH. However, N103S missense mutation is predicted to disrupt the secondary structure of human BMP15 protein and is weakly associated with OHSS. This coding mutation of the BMP15 gene may partially explain the results obtained during our research. Using Thesias software, we reconstructed haplotypes with the four intragenic variants and calculated their frequencies in normal and over-responders to rFSH. The haplotype TGGA was over-represented in high responders when compared with the rest of patients. Moreover, this association was higher in patients with OHSS, with a significant global haplotypic effect of the BMP15 gene.
Conclusion Our results suggest a direct relationship between increased follicle production during COS and BMP15 alleles in response to rFSH in humans. The use of BMP15 markers to prevent OHSS is also a possibility that requires thorough evaluation. 
Introduction
To obtain better pregnancy rates in assisted reproduction techniques (ART), exogenous gonadotropins are widely used during controlled ovarian stimulation (COS) protocols. Nowadays, recombinant follicle-stimulating hormone (rFSH) is the main treatment employed in ART [1] , and several studies have shown high variability in clinical outcome in women undergoing FSH treatment. This variability may depend on factors such as age of patients, ovarian reserve, or endocrine status [2] . The ovulation rate in mammals is determined by a complex exchange of hormone signals between the pituitary gland and the ovary, and by a paracrine crosstalk between the oocyte and its adjacent somatic cells (granulosa and theca cells). The use of gonadotropin-releasing hormone (GnRH) agonists (GnRHa) is very important in ovarian stimulation protocols to suppress oestrogen production in the ovary via biochemical ablation of the hypothalamushypophysis-ovary axis (pituitary suppression). Consequently, COS pharmacogenetics provide an unique opportunity to study the regulation of ovarian oestrogen and follicle production. Calculation of the rFSH dosage in a specific patient is performed empirically and/or on the basis of previous results and therefore all oestrogen production is controlled by exogenous rFSH pharmacologically.
Usually, COS treatments give rise to different types of ovarian response, there being two extreme situations: patients with lower than normal response (poor responders) and patients with a high response to gonadotropins (high responders). Moreover, these last patients have a substantially higher risk of developing ovarian hyperstimulation syndrome (OHSS) and associated complications [3] .
OHSS is a well-known iatrogenic complication of ovulation induction and it can be accompanied by severe morbidity that could be fatal. The clinical course of OHSS may involve, according to its severity and the occurrence of pregnancy, cardiovascular effects, electrolytic imbalance, pulmonary manifestations, neurohormonal and haemodynamic changes and can contribute to arteriolar vasodilatation, hepatic anomalies, hypoglobulinaemia, febrile morbidity, thromboembolism, neurological manifestations, and adnexal torsion [4] . Therefore, the detection of patients with an increased risk of developing OHSS is a serious clinical problem, and multiple biomarkers in different and unrelated biochemical pathways, such as oestradiol [5] , renin-angiotensin system [6, 7] , cytokines [8] [9] [10] , inhibins [11] and soluble selectins [12] , have been evaluated as potential OHSS predictors. Ovarian hyperstimulation entails very high serum oestradiol levels and altered progesterone/oestradiol ratios. So far, a limited number of fatal cases have been reported [13] [14] [15] [16] .
We and others are interested in the study of genes implicated in COS outcome using the pharmacogenetic approach (reviewed in reference 3). There is enough evidence of genetic markers involved in poor response during COS treatment in women. Georgiu et al. studied common PvuII and rare BstUI restriction fragment length polymorphisms (RFLPs) within the ESR1 gene and suggested that ESR1 alleles might affect pregnancy rate and oocyte ratio during in-vitro fertilization (IVF) [17] . Sundarrajan et al. partially replicated this work and, moreover, they found that ESR1 PvuII PP carriers had lower follicle and oocyte numbers observed during COS [18] . The Ser680Asn polymorphism in the FSHR gene was also associated with FSH basal level and elevated gonadotropin requirements during COS [19, 20] . In addition, we recently proposed that the same polymorphism at the FSHR locus acts as a low-penetrance allele related to COS outcome and could be dependent on the basis of a complex multifactorial model [21] . We also detected an oligogenic model, including specific FSHR, ESR1 and ESR2 genotype patterns, related to the poor response to FSH hormone during COS treatment [22] . [27] . Females carrying homozygous mutations compromising BMP15 activity displayed follicular development arrests at the primary stage with an early block in folliculogenesis, resulting in infertility. In contrast, heterozygotes exhibited an increased ovulation rate and multiple pregnancies. Therefore, BMP15 appears to be associated with mechanisms of infertility and super fertility in a dosage-sensitive manner [27] .
BMP15 protein is a member of the transforming growth factor-b (TGF-b) superfamily of proteins. This superfamily controls many aspects of development by binding and activating two types of transmembrane serine/threonine kinase receptors and SMAD (signalling mothers against decapentaplegic homologue) proteins to regulate cellular functions [28] . Given the relative importance of these factors in the intraovarian regulation of follicular development and its involvement in ovulation rate, we considered BMP15 to be a good candidate gene for COS pharmacogenetic analysis.
Here, we present a genetic association study of COS outcome in 307 unrelated women with normal ovarian function who underwent COS using rFSH. We analysed four single nucleotide polymorphisms located at the BMP15 gene in order to investigate the role of this gene in relation to COS outcome. Our results support the hypothesis that BMP15 alleles predict over-response to rFSH and ovarian hyperstimulation syndrome in humans.
Materials and methods

Patients
The referral centre is the Hospital Príncipe de Asturias de Alcalá de Henares (Madrid, Spain). 307 Caucasian women undergoing IVF or intracytoplasmic sperm injection (ICSI) techniques were recruited retrospectively during this work (all patients underwent IVF or ICSI, and later on they were called and included in this study). The mean ± SD age of patients was 32.6 ± 2.6 years. The causes of infertility in selected women were male factor (174 cases), tubal factor (90 cases) or both of them (43 cases). Ovulation in all patients included was conserved (patients with dysovulation were excluded). Evaluation of the response to FSH in women was performed using standard criteria and previously published parameters [21] .
The study design was retrospective. All patients were treated with rFSH to achieve COS. GnRH analogue was administered to all women included in our study according to the minimal monitoring method described by Wikland et al. [29] . Briefly, oestradiol levels of all patients were down-regulated with a GnRH agonist according to a long protocol permitting fairly precise programming of the oocyte collection (triptorelin 0.1 mg/ day over 15 days to reach oestradiol values r 40 pmol/l). Once minimal oestradiol values were obtained, the women were treated with 100-200 IU/day of human rFSH for 11 consecutive days. Follicular development and growth were evaluated by transvaginal sonography after 6 days of stimulation and then every other day. Ovulation was induced by a single injection (5000-10 000 IU) of human chorionic gonadotropin in women with at least three follicles with a diameter Z 18 mm. Oocytes were obtained by conventional methods as previously reported [21] . Conventional IVF or ICSI was carried out in accordance with original protocols [30, 31] .
To perform phenotype-genotype correlations and endocohort analyses, we decided to divide our population according to follicle production in COS outcome. Thus, we defined two groups: high responders, with patients producing Z 12 follicles (90th percentile) (n = 35), and no high responders, with patients producing < 12 follicles (n = 272) ( Table 1) . In order to test the predictive value of genetic markers for OHSS, we also analysed separately an additional group within high responders in COS, consisting of those women showing early symptoms or biochemical data of this rare adverse effect as the strongest endpoint of rFSH over-response (n = 11). Thus, the treatment was cancelled in all patients who showed any early manifestation of OHSS. This treatment cancellation was carried out when the serum oestradiol levels are > 5000 pmol/l, or when these levels are between 3000 and 5000 pmol/l, with low body mass index and/or high ovarian reserve in the first sonographic surveillance.
Written informed consent was obtained from all patients participating in the present study. The protocol was approved by the Institutional Review Board of the Hospital Príncipe de Asturias (Alcalá de Henares, Madrid, Spain).
DNA extraction
We obtained 5 ml of peripheral blood from all patients to isolate germline DNA from leukocytes. DNA extraction was performed according to standard procedures using the Nucleospin Blood Kit (Macherey-Nagel, GmbH, Düren, Germany). Aliquots of DNA at a concentration of 5 ng/ml were prepared to perform PCR. The rest of the stock was cryopreserved at -201C.
Mutation analysis
The DNA sequence used to carry out this study corresponds to the genomic sequence of BMP15. The genomic sequence containing the BMP15 gene (Genomic Contig NT_011638, locus ID 9210) was identified using the BLAT tool at UCSC (University of California Santa Cruz) Genome Bioinformatics server (http://www.ucsc. edu). The gene is di-exonic (328 bp and 851 bp respectively), spans 5823 bp and is located at Xp11.2 ( Fig. 1a) . Information concerning any single nucleotide polymorphism (SNP) identified was compared with the UCSC Genome Bioinformatics and also with Genbank Database at the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). Automated DNA sequencing methods were employed to scan the entire coding region of the BMP15 gene in selected specimens. Overlapping PCRs covering the coding sequence (including 5 0 and 3 0 UTR regions) of gene were designed. PCR products were purified and bidirectionally sequenced using the corresponding primers (Supplementary Table 1a ). Sequencing reactions were performed using the CEQ Dye Terminator Cycle Sequencing Quick Start Kit (Beckman Coulter, Inc.,), according to the manufacturer's instructions, and analysed using CEQ 8000 Genetic Analysis System (Beckman Coulter, Inc., Fullerton, California, USA).
Genotyping of polymorphisms within the BMP15 gene using pyrosequencing technology
A total of four SNPs were analysed (Supplementary Table  1b ). All genotypes were carried out by using the pyrosequencing technology protocols [32] . Assays were run on a thermal cycler machine (MJ Research Inc., Waltman, Massachusetts, USA) using a final volume of 20 ml. The selected primers for pyrosequencing analysis and PCR conditions are shown in Supplementary Table 1(b). The pyrosequencing machine was programmed in accordance with the manufacturer's recommendation. Figure 2 (a) shows genotype results from pyrosequencing.
Constructs and cell culture transfections
The 5 0 UTR (5 0 untranslated region) of BMP15 was amplified to a final volume of 10 ml containing 10 ng of genomic DNA, 0.2 mmol/l each amplification primer, 1.5 mmol/l MgCl 2 , 75 mmol/l dNTP and 1 U of High fidelity Taq Polymerase (Roche Diagnostics, Germany). Primers, including XhoI and NcoI restriction sites, and PCR conditions are described in Supplementary Table 1(c). Amplicons were purified, digested and cloned into pGL3-Basic vector (Promega, Madison, Wisconsin, USA). Ligation reactions were performed using a rapid ligation kit (New England Biolabs, Beverly, Massachusetts, USA) according to the manufacturer's instructions. Then, plasmids were chemically transformed to XL1-Blue competent cells. Colonies were checked for the presence of the insert and, positive constructs were sequenced to discard the constructs bearing point mutations incorporated during the PCR. As a result we obtained pTG9 for studying the mutant haplotype and pCC43 as a wild-type vector. These two plasmids were also shuffled in order to isolate each single SNP within the vector. Thus we obtained pTC2 and pCG15 (Supplementary Table 2 ).
Indeed, pGL3-control was digested with BamHI/XbaI and a 0.3 kb fragment containing the SV40 enhancer was isolated. This sequence was cloned downstream of the Luc gene of pCC43, pTG9, pTC2, pCG15 and pGL3-basic vectors, thus generating pECC, pETG, pETC, pEGG and pGL3-enhancer. Clones were sequenced and prepared for cell culture transfection.
Du145, MCF-7, K562 and GH3 cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) or MEM supplemented with 20% fetal calf serum at 371C in 95% humidified air and 5% CO 2 .
Statistical analysis
To compare quantitative variables among groups, mean values were analysed by using Analyse-It (version 1.65; Analyse-It Software Ltd, Leeds, UK) software for the Kruskall-Wallis test (for non-normally distributed data).
To perform statistical analysis of genotype distribution, the test for deviation from Hardy-Weinberg equilibrium or two-point association studies, we employed tests adapted from Sasieni [33] without a Bonferroni-type correction because the detected polymorphisms are in complete linkage disequilibrium (LD). These calculations were performed at the online resource of the Institute for Human Genetics, Munich, Germany (http:// ihg.gsf.de).
LD values between markers, haplotype construction and haplotype analysis for dichotomic traits were performed using Thesias software (http://www.genecanvas.org) based on the SEM algorithm [34] . Age-adjusted haplotype analysis for quantitative traits (oestradiol levels and number of follicles) was also carried out using Thesias software. This method allows one to estimate haplotype effects by comparison to a reference (the intercept) taken here as the most frequent one.
Regarding the bioinformatics tools used for the sequence analysis of the 5 0 UTR in BMP15 gene, it should be stated that Translational Element Search System (TESS) software is available at http://www.cbil.upenn.edu/tess. Dragon Oestrogen Response Elements (ERE) Finder software was also online interrogated at http://sdmc. lit.org.sg/ERE-V2/index.
Results
Genotype analysis
We analysed 307 patients undergoing COS for the allelic frequency and genotype distribution of two selected polymorphisms located at the 5 0 UTR, identified as -9C > G (rs3810682), and in intron 1, identified as IVS1 + 905A > G locus (rs3897937) of the BMP15 gene. Allelic frequencies in our sample were 0.76 for C allele and 0.24 for G allele in the -9C > G locus and 0.69 for A allele and 0.31 for G allele in intron 1 IVS1 + 905A > G locus. The observed heterozygosity was 0.39 and 0.46 respectively. We observed that the genotype frequencies were in accordance with Hardy-Weinberg equilibrium (P > 0.68). 
BMP15 gene in COS outcome
A two-step analysis was conducted. In the first step, we released a preliminary association studies dividing patients into poor ( r 3 follicles), high ( Z 12 follicles) and normal responders (between 4 and 11 follicles). Differences in genotype distributions for two polymorphisms were explored using chi-squared tests adapted from Sasieni [33] . Preliminary statistical results indicated that high responder patients have a different allelic frequency and genotype distribution in both markers of the BMP15 gene when compared to normal responders. In contrast, poor responders do not display any significant association compared with normal responders (data not shown).
Therefore, we focused our studies only on patients with high follicle production and treated women were divided into two groups, patients producing Z 12 follicles (high responders) and patients producing < 12 follicles (no high responders), as previously described under methods. The chi-squared tests adapted from Sasieni ( 
Gene sequencing
We determined the complete coding sequence, 1 kb upstream of ATG and 3 0 UTR of the BMP15 gene in 35 high responders (including 11 OHSS women) using bidirectional automated capillary DNA sequencing. We identified two new single nucleotide DNA variants. The first one appeared again in the 5 0 UTR, and it was identified as -673C > T. The other mutation appeared in the exon 1 c.308A > G locus and resulted in a missense mutation in codon 103 of the protein (N103S) (Fig. 1). A second step was conducted using these new variants, and we again investigated its allelic frequency and genotype distribution in 307 patients undergoing COS. Allelic frequencies in our patients were 0.76 for C allele and 0.24 for T allele in the -673C > T polymorphism and the observed heterozygosity for the locus was 0.39 (similar results to the -9C > G locus). In the N103S locus the allelic frequencies were 0.94 for allele N103 and 0.06 for allele S103 and the observed heterozygosity for this locus was 0.10. The genotype frequencies are in accordance with Hardy-Weinberg equilibrium (P > 0.58).
The N103S variant does not show a different allelic frequency and genotype distribution when we compare high responders to the rest of patients. Interestingly, when we separated the patients with early symptoms or biochemical data of OHSS, because it is the hardest endpoint of FSH over-response, we observed that 3 out of 11 OHSS women (27.3%) carried the N103S variant in heterozygous state. By contrast, 3 out of 24 high responders (OHSS women excluded) (12.5%) and 27 out of 272 no high responders (9.9%) carried the N103S variant. In this regard, over-representation of N103S in OHSS women compared with no OHSS women, is close to statistical significance (OR = 3.53, CI = [0.88-14.15], P = 0.06 for heterozygous test). However, these variants only partially explain the results obtained during association studies. This data points to the existence of other variants close to the BMP15 gene involved in over-response to rFSH and OHSS. For this reason, we decided to re-construct haplotypes of the BMP15 gene using the four validated genetic variants looking for haplotypes in LD with the putative functional variant of the BMP15 gene.
Haplotype analysis
In order to analyse the degree to which these polymorphisms are in LD, we performed standardized pairwise LD (D 0 ) using Thesias software. The value D 0 of ± 1 indicates complete LD, positive when the rare allele of each polymorphism is preferentially associated and negative when the rare and frequent alleles are associated [35] . Thus, we verified that -673C > T locus is a syntenic variant of the -9C > G locus with the same allelic frequencies and in complete LD and the four polymorphisms are in complete LD between them (D 0 > 0.95 and P < 0.004).
Using Thesias software, we reconstructed haplotypes and calculated their frequencies, although rare haplotypes with minor-allele frequencies of less than 5% were excluded. The program identified four distinct haplotypes for combinations and permutations from each genotype of four polymorphisms in our population, TGGA, TGGG, CCGA and CCAA for -673C > T, -9C > G, IVS1 + 905A > G and N103S polymorphism respectively (Table 2) .
Differences in haplotype distribution between high responders and no high responders was significant (Pearson Chisquare with 3 df = 8.51; P = 0.04). Two haplotypes were statistically significant: haplotype CCAA is a protective allele (OR = 0.53, CI = [0.31-0.91], P = 0.02), whereas haplotype TGGA, which is over-represented in high responders when compared versus no high response patients (30% versus 17.6%), is a risk allele (OR = 2.00, CI = [1.10-3.60], P = 0.02) for women in COS overresponse. This phenomenon is due to 'contrary genetic sweep', where the over-representation of one haplotype may lead to the reduction of the other haplotype.
Intriguingly, the haplotype carrying N103S amino acid change (TGGG in Table 2 ), though, it does not reach statistical significance, has almost identical OR to TGGA haplotype. In fact, analysis of the haplotypic background showed no effect difference between presence of the A or G allele at TGG-background (P = 0.95), suggesting that TGG(G/A) haplotype (including TGGG and TGGA alleles) carries a functional variant involved in rFSH over-response. However, given the over-representation of N103S in OHSS women compared with non-OHSS women, observed in genotype analysis, and its low population frequency, we cannot discard that the N103S locus or other linked variant could modify rFSH response in COS. Alternatively, and using our marker set, we can not rule out the fact that both haplotypes (TGGG and TGGA) might share the same founding mutation.
Given that N103S is not informative about the TGGbackground, we repeated this study with the other three markers alone. We observed that the statistical significance for the global haplotypic effect was slightly increased with respect to the four markers haplotype analysis (Pearson chi-square with 2 df = 8.56; P = 0.01). The TGG haplotype, according to the previous analysis, is associated with increased risk of rFSH over-response (OR = 2.15, CI = [1.23-3.73], P = 0.005).
Furthermore, when we compared the patients with early symptoms or biochemical data of OHSS, versus the rest of the patients (no OHSS), we observed a strong positive association with TGG haplotype (OR = 3.95, CI = [1.55-10.10], P = 0.002). In fact, haplotype frequencies were inverted in OHSS patients with a significant global haplotypic effect on the BMP15 gene (Pearson chi-square with 2 df = 11.21; P = 0.004) (Fig. 3) . These last results point to the presence of one or more functional mutations in the haplotype background TGG(G/A) associated with a high follicle production phenotype and OHSS in our population. In addition, our results also suggest that the putative functional mutations may have different molecular mechanisms.
We found no associations with any haplotype in the QTL analysis of peak oestradiol or follicle production. That could be due to the fact that OHSS women are included in the high responders group and we have no information about the final number of follicles production in them, due to early cancellation. However, a trend towards association was obtained for peak oestradiol in haplotype TGGA (n = 298, P = 0.08).
Functional studies
In addition to the missense mutation detected, DNA variations located at 5 0 UTR of the BMP15 gene might also be functional. In order to perform a functional characterization of the sequence under study, we cloned 1 kb upstream of the BMP15 gene of both CCAA/CCAA (wildtype) and TGGA/TGGA (mutant) women. As stated in Materials and Methods, four constructs were initially tested and their luciferase activity was compared to the promoter-less vector. pRL-null vector containing the Renilla luciferase gene was included for internal normalization, allowing inter-and intra-experimental comparison.
Different cell lines were transfected following previous experimental procedures, and Luc activity was determined after a 24 and 48 h incubation. In order to test different genetic backgrounds, four cell lines were included in this study: Du145, MCF-7, K562 and GH3. After three independent experiments, we concluded that no expression differences could be detected among the constructs after normalization. In addition, luciferase activities were similar to those obtained with the pGL3-basic (promoter-less control). This led us to propose that specific activation signals may be required for triggering expression from our vectors in transfected cells.
A detailed in-silico analysis of the BMP15 5 0 UTR using both TESS and Dragon ERE Finder software programs, highlighted an oestrogen receptor element (ERE) located 80 bp upstream from the initial ATG (Fig. 1b) . For this reason we stimulated transfected MCF-7 cells with 5 nmol/ l of 17-alpha ethinyloestradiol [36] . Luciferase activity was measured at 0, 0.5, 1, 4, 8 and 24 h post-induction. No differences were observed between constructs bearing the wild-type and mutant 5 0 UTR haplotypes (data not shown). Moreover, no up-regulation was detected during any experiment. We also considered the possibility that the ERE was exerting a negative effect on 5 0 UTR activity. This regulatory effect may be due to the oestrogenic activity of the phenol-red from the culture media [37] . In order to eliminate this possibility, transfected MCF-7 was cultured in a red-free medium, with identical results.
Previous studies in mice linked BMP15 expression via stimulation with FSH. Therefore, we looked for 
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differential promoter activities of the candidate plasmids under these conditions. After transfection, Du145 were cultured in serum-free media with/without 0.1 U/ml FSH (Sigma-Aldrich, St Louis, Missouri, USA) [38] . As for the above-mentioned experiments, Luc expression was measured following a time-course kinetic. Again, no induction was observed upon stimulation and no promoter activity was detected in cultures transfected with our plasmids series (data not shown).
Some authors have described the negative feedback circuit linking the oocyte and the granulosa cells involving Kit ligand [39] . Therefore, we proposed that by stimulating with Kit ligand we might modulate BMP15 promoter expression. For this purpose, we electroporated the K562 cell line, which is known to express an active Kit receptor [40] . Identical kinetic analyses were performed and neither promoter activity nor differences between constructs were observed.
Finally, each kinetic analysis was repeated using the plasmids containing the SV40 enhancer. Because identical results were obtained we concluded that: (1) the 1 kb upstream from the initial ATG codon does not contain the minimal promoter sequence of BMP15; or (2) that specific transcription factors expressed in the oocyte are required for triggering BMP15 expression; and/or (3) that alternative (or additional) stimuli should be present in order to promote transcription initiation of the sequence under study. Finally, we should also consider the possibility that the tight control of BMP15 expression might be mediated through the action of specific repressors present in non-oocyte cells.
Discussion
Several studies have shown high variability in clinical outcome of women undergoing COS using rFSH hormone [3] . In this regard, there are two opposite situations involved in COS outcome, a poor or a high response inducing OHSS. The existence of genetic factors involved in poor response has been described in previous studies [17] [18] [19] [20] [21] and we have presented direct evidence of the polygenic nature of the COS trait in humans [22] . In contrast, there are not many studies for genetic markers associated with over-response to FSH or high follicle production. However, Daelemans et al., in a recent genetic study of the Ser680Asn polymorphism of the FSHR gene, suggest that the genotype in position 680 of the FSHR cannot predict which patients will develop OHSS, but it could be a predictor of severity of symptoms among OHSS patients [23] .
In this way, and employing the candidate gene approach, we selected the BMP15 locus to explore its involvement in COS outcome in women undergoing assisted reproductive techniques using rFSH hormone. BMP15 is a good candidate gene because in animal models other groups have demonstrated the important role in ovarian development and folliculogenesis played by the action of the BMP15 protein. Five separate point mutations in the BMP15 gene have been identified affecting the ovulation rate in ewes [27, 41, 42] and BMP15 knock-out female mice are subfertile and show reduced ovulation rates after gonadotropin treatment [43] . The analysis of the results obtained in both models suggests that BMP15 may not affect follicular development and ovulation rate in the same way in all mammal species. We analysed the clinical outcome of 307 COS cycles and the role of four polymorphisms ( -673C > T, -9C > G, IVS1 + 905A > G and N103S) located within the BMP15 gene in rFSH efficacy. Our results support the hypothesis that the BMP15 locus may not be implicated in poor response ( r 3 follicles) to COS. In contrast, we have enough evidence regarding the existence of association among three linked markers within the BMP15 gene with high follicle production in women undergoing rFSH stimulation (high responders, Z 12 follicles). This result could be due to population stratification. To ensure that our population did not present selection bias or population stratification, we repeated the allele frequency and genotype distribution in the BMP15 gene for a population including 1210 unrelated postmenopausal women and we observed a similar allele frequency and genotype distribution (data not shown). This result is in accordance with previous observations of Galloway et al. in ewes with heterozygous FecX I mutant females that exhibited increased ovulation and lambing rates [27] . These observations indicate that high responder women might have a functional variant close to the BMP15 locus involved in COS outcome. Moreover, an independent study in a family affected by hypergonadotropic ovarian failure identified a heterozygous non-conservative substitution (Y235C) in the pro-region of the BMP15 allele in two sisters affected by this Mendelian phenotype [44] . This observation reinforces the role of our candidate in ovarian physiology and underlines the fact that the BMP15 signalling pathway is also important for folliculogenesis and/or ovarian development in humans.
When we sequenced the functional BMP15 gene in 35 over-responder women, the non-conservative mutation described by Di Pasquale et al. (the only BMP15 mutation described for humans to date) was not identified in the Spanish population. However, a new missense variant, N103S, was identified and, its association with iatrogenic OHSS is close to reach statistical significance. Nevertheless, the functionality of the N103S variant needs further characterization. Although statistical analyses indicate that N103S might partially explain the genetic association detected, results from the TGG(G/A) haplotype analysis clearly suggest that another functional variant must be involved in COS over-response.
We suspect that some mutations of 5 0 UTR of the BMP15 gene could be related to the COS outcome phenotype. Therefore we fused the 1 kb 5 0 UTR plus the first four BMP15 amino acids to the luciferase reporter gene in order to determine the Luc enzymatic activity expressed in both the wild-type and mutant BMP15 haplotypes. However, no expression differences were detected among the constructs after normalization. The reason for the lack of functionality of these haplotypes in these experiments requires detailed discussion. We feel that specific repression sequences, including the YY1/delta factor found in the 5 0 UTR and promoter region of the human BMP15 gene, impaired the proper activation of the putative minimal promoter outside oocyte cells (data not shown). In view of this, specific oocyte-derived transcription factors might be necessary to activate the human BMP15 promoter.
On the basis of this hypothesis, several mechanisms were tested using previous results in animal models. BMP15 is a potent stimulator of granulosa cell growth and promotes the progression of folliculogenesis from the primary stage to the FSH-dependent stage [45] . BMP15 has a double function in granulosa cells, since there is a negative feedback system between oocyte and granulosa cells, where BMP15 stimulates Kit ligand expression and mitotic activity in granulosa cells, whereas Kit ligand is a potent inhibitor of BMP15 mRNA expression in oocytes [39] . On the other hand, BMP15 inhibits FSH action by suppressing FSHR expression [46] and FSH plays an essential role in folliculogenesis and female fertility; for example, FSH promotes proliferation and differentiation of preantral follicles via paracrine factors such as insulin growth factor-1 and activin [47, 48] . In addition, FSH is crucial for an appropriate modulation of Kit ligand and BMP15 in promoting oocyte growth [49] .
Our preliminary functional studies did not prove that a functional mutation in BMP15 5 0 UTR exists. It is possible that our approach is not suitable for assessing the function, due to the lack of expression outside of oocyte cells. A possible reason for this is that an additional sequence up-and/or down-stream would be necessary for transcription initiation.
In conclusion, although we obtained enough genetic evidence of BMP15 gene involvement in COS overresponse and OHSS, the molecular mechanism for the genetic association observed remains unclear. Perhaps the N103S variant itself, or a different variation linked to TGG(G/A) haplotype in the BMP15 gene or in another gene in tight linkage disequilibrium, could be the principal cause of over-response in COS associated with the BMP15 haplotypes that we detected.
For a complete understanding and corroboration of our findings the analysis of the BMP15 gene in independent populations would be necessary. Furthermore, we have studied women with conserved ovulation (women with dysovulation were excluded) since patients with polycystic ovarian syndrome are considered at high risk for the development of OHSS [4] . However, it could be of interest to analyse the role of BMP15 genes in patients with polycystic ovarian syndrome. Functional characterization of BMP15 N103S protein and risk haplotypes detected would be necessary to delineate a mechanistic hypothesis of BMP15 involvement in COS outcome in humans.
BMP15 gene in COS outcome
Our results suggest the existence of a new pathway for activating oestrogen and follicle production in humans as it occurs in other mammals. Thus, and according to data provided by sheep and mouse models, a reduced level of BMP15 might result in higher levels of FSHR in the granulosa cells, high levels of oestrogens, activated Kit ligand (a potent inhibitor of BMP15 mRNA expression in oocyte) and increased follicle production with the possible presentation of a side effect related to gonadotropin hypersensitivity and OHSS.
Predicting which patients will develop OHSS during COS is one of the main challenges for the clinician involved in assisted reproductive techniques [3] . Our results are the first to show a direct link between increased follicle production and BMP15 alleles during controlled ovarian hyperstimulation and provide a new potential tool which may be useful in human pharmacogenetics studies of COS treatment and OHSS prediction.
